These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38987434)

  • 1. Response to chemotherapy could predict the prognosis of esophageal squamous cell carcinoma treated with neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) followed by surgery: long-term results in a single institute.
    Sato Y; Mori K; Atsumi S; Sakamoto K; Oya S; Okamoto A; Urabe M; Miwa Y; Yajima S; Yagi K; Nomura S; Yamashita H; Seto Y
    Esophagus; 2024 Oct; 21(4):514-522. PubMed ID: 38987434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
    Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
    Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
    Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
    Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
    Sugimura K; Miyata H; Shinno N; Ushigome H; Asukai K; Yanagimoto Y; Hasegawa S; Takahashi Y; Yamada D; Yamamoto K; Nishimura J; Motoori M; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
    Oncology; 2019; 97(6):348-355. PubMed ID: 31461716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
    Yamasaki M; Yasuda T; Yano M; Hirao M; Kobayashi K; Fujitani K; Tamura S; Kimura Y; Miyata H; Motoori M; Shiraishi O; Makino T; Satoh T; Mori M; Doki Y
    Ann Oncol; 2017 Jan; 28(1):116-120. PubMed ID: 27687307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of Initial Tumor Reduction as a Prognostic Factor in Esophageal Squamous Cell Cancer Patients Undergoing Neoadjuvant Chemotherapy Followed by Surgery : A Retrospective Cohort Study.
    Hagi T; Shiraishi O; Nakanishi T; Kohda M; Hiraki Y; Kato H; Yasuda A; Shinkai M; Imano M; Yasuda T
    Ann Surg Oncol; 2024 Aug; 31(8):5064-5074. PubMed ID: 38664331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative docetaxel, cisplatin, and 5-fluorouracil for resectable locally advanced esophageal and esophagogastric junctional adenocarcinoma.
    Hirose T; Yamamoto S; Honma Y; Yokoyama K; Hirano H; Okita N; Shoji H; Iwasa S; Takashima A; Ishiyama K; Oguma J; Daiko H; Maeda S; Kato K
    Esophagus; 2024 Jul; 21(3):328-335. PubMed ID: 38467986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
    Kobayashi K; Kanetaka K; Yoneda A; Kobayashi S; Maruya Y; Isagawa Y; Yoshimoto T; Migita K; Kawaguchi Y; Kuba S; Morita M; Okada S; Kosaka T; Yamaguchi S; Inoue Y; Adachi T; Hidaka M; Torashima Y; Ito S; Takatsuki M; Eguchi S
    J Gastrointest Cancer; 2021 Jun; 52(2):582-592. PubMed ID: 32524305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes and safety of radical transmediastinal esophagectomy with preoperative docetaxel, cisplatin, and 5-fluorouracil combination chemotherapy for locally advanced squamous cell carcinoma of the thoracic esophagus.
    Yamagata Y; Saito K; Hirano K; Oya M
    World J Surg Oncol; 2020 Sep; 18(1):252. PubMed ID: 32962718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma: Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan.
    Matsuda S; Kitagawa Y; Takemura R; Okui J; Okamura A; Kawakubo H; Muto M; Kakeji Y; Takeuchi H; Watanabe M; Doki Y
    Ann Surg; 2023 Jul; 278(1):e35-e42. PubMed ID: 35837977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
    Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
    World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial.
    Kato K; Machida R; Ito Y; Daiko H; Ozawa S; Ogata T; Hara H; Kojima T; Abe T; Bamba T; Watanabe M; Kawakubo H; Shibuya Y; Tsubosa Y; Takegawa N; Kajiwara T; Baba H; Ueno M; Takeuchi H; Nakamura K; Kitagawa Y;
    Lancet; 2024 Jul; 404(10447):55-66. PubMed ID: 38876133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
    Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
    World J Surg; 2019 Aug; 43(8):2006-2015. PubMed ID: 30972432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Triplet Chemotherapy with Docetaxel, Cisplatin plus 5-Fluorouracil versus Docetaxel, Cisplatin plus S-1 for Advanced Esophageal Squamous cell Carcinoma: Propensity Score Matched Analysis.
    Kitadani J; Ojima T; Hayata K; Goda T; Takeuchi A; Tominaga S; Fukuda N; Nakai T; Yamaue H; Kawai M
    Oncology; 2024; 102(3):228-238. PubMed ID: 37708864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
    Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
    Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer.
    Okamoto H; Taniyama Y; Sakurai T; Heishi T; Teshima J; Sato C; Maruyama S; Ito K; Onodera Y; Konno-Kumagai T; Ishida H; Kamei T
    Esophagus; 2018 Oct; 15(4):281-285. PubMed ID: 29948480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma.
    Loc NVV; Vuong NL; Trung LV; Trung TT
    J Gastrointest Cancer; 2023 Dec; 54(4):1240-1251. PubMed ID: 36723785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.